RANDOX PLAYSAFE
LIVE

Serial Number

98404514

Owner

Randox Laboratories Limited

Attorney

Douglas N. Masters

Filing Date

Feb 13, 2024

Add to watchlist:

No watchlists yet
View on USPTO

RANDOX PLAYSAFE Trademark

Serial Number: 98404514

RANDOX PLAYSAFE is a trademark filed by Randox Laboratories Limited on February 13, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

Randox Laboratories Limited (18 trademarks)

Ardmore
Co. Antrim , GB

Entity Type: 99

Trademark Details

Filing Date

February 13, 2024

Registration Date

Not Registered

Published for Opposition

January 14, 2025

Goods & Services

Chemicals for use in industry, science and photography, as well as in agriculture, horticulture and forestry, except fungicides, herbicides, insecticides, and parasiticides; Diagnostic preparations for scientific purposes; Chemical reagents, other than for medical or veterinary purposes; Enzymes and proteins for industrial use; Diagnostic preparations for analysis of food products and water for scientific and research purposes; Clinical diagnostics preparations for scientific use; Diagnostic scanning agents for scientific use; Diagnostic testing materials for scientific use; Replacement parts and fittings for all the aforesaid goods

Medical services; hygienic and beauty care for human beings; consulting services relating to health care; health advice and information services; medical care services; health clinic services; healthcare services; medical consultations and lifestyle consultations, namely, professional consultations to individuals to assess their personal health and wellbeing; medical health assessment services; health screening services; diagnostic health screening services; preparation of reports relating to health care matters; professional consultancy relating to health; medical testing; medical diagnostic testing; nursing services; nursing care services; medical health and fitness assessment services; medical advisory and consultancy services relating to immunology; advisory and consultancy services relating to nutrition; cholesterol testing; genetic testing for medical purposes; hearing tests; services for the testing of blood; services for the testing of sera; services for the testing of urine; services for testing of bone functions; services for testing of major body organs; services for the testing of fertility hormone levels; health screening for pregnant women; pregnancy testing; prenatal care services; postnatal care services; services for the testing of diabetes; services for the testing of thyroid function; services for testing iron levels; medical assistance; medical clinics; information, consultancy and advice relating to any of the aforesaid services

Pharmaceutical, veterinary and sanitary preparations and substances for use in medical clinical analysis and testing in connection with diagnosing cardiovascular diseases, coronary heart disease, brain diseases, cancer, diabetes, kidney diseases, renal diseases, anemia, dementia, nervous system dysfunctions, diseases of the central nervous system, autoimmune diseases, allergy, vascular diseases, infertility, menopause, early or delayed puberty, reproductive or non-reproductive disorders, gastrointestinal disorders, digestive diseases and conditions, metabolic diseases, hypercalcemia, thyroid diseases, bone disorders, respiratory diseases, infectious diseases, sexually transmitted diseases, and urinary tract infections, testing high or low levels of testosterone, testing for calcium absorption, testing of blood levels, antimicrobial testing, and screening for drug use; blood sera and blood anti-sera, for medical and veterinary use; diagnostic preparations for medical purposes; diagnostic preparations and substances for medical and veterinary purposes; kits for medical purposes comprised of pharmaceutical preparations for use in medical clinical analysis and testing in connection with diagnosing cardiovascular diseases, coronary heart disease, brain diseases, cancer, diabetes, kidney diseases, renal diseases, anemia, dementia, nervous system dysfunctions, diseases of the central nervous system, autoimmune diseases, allergy, vascular diseases, infertility, menopause, early or delayed puberty, reproductive or non-reproductive disorders, gastrointestinal disorders, digestive diseases and conditions, metabolic diseases, hypercalcemia, thyroid diseases, bone disorders, respiratory diseases, infectious diseases, sexually transmitted diseases, and urinary tract infections, testing high or low levels of testosterone, testing for calcium absorption, testing of blood levels, antimicrobial testing, and screening for drug use; clinical diagnostics preparations, for medical or veterinary use; clinical diagnostic reagents for in vitro and vivo use; diagnostic scanning agents for in vivo use; diagnostic testing materials for medical and veterinary use; clinical medical reagents; reagents for use in diagnostic tests for medical and veterinary purposes; reagents for use with analyzers for medical and veterinary purposes; replacement parts and fittings for all the aforesaid goods

Medical diagnostic kits, consisting of containers, analyzers and disposable cartridges, namely, apparatus for processing, testing and analyzing of bodily fluids; medical diagnostic kits, consisting of containers, analyzers and disposable cartridges, namely, apparatus for testing or detecting sexually transmitted infections (STI); clinical laboratory analytical instruments for medical or veterinary use, namely, for the analysis of bodily fluids, for use in in vitro diagnostic testing procedures, and for use with clinical chemistry analyzers, blood testing apparatus, and diagnostic saliva vials

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Mar 10, 2026 EXRA
SOU EXTENSION 2 GRANTED
Mar 9, 2026 EX2G
SOU EXTENSION 2 FILED
Mar 9, 2026 EXT2
SOU TEAS EXTENSION RECEIVED
Mar 9, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 15, 2025 EXRA
SOU EXTENSION 1 GRANTED
Sep 5, 2025 EX1G
SOU EXTENSION 1 FILED
Sep 5, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Sep 5, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Mar 11, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 14, 2025 NPUB
PUBLISHED FOR OPPOSITION
Jan 14, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 8, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 19, 2024 CNSA
EXAMINER'S AMENDMENT ENTERED
Dec 19, 2024 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 19, 2024 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 19, 2024 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 19, 2024 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 4, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 4, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 4, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sep 6, 2024 GNRN
NON-FINAL ACTION E-MAILED
Sep 6, 2024 GNRT
NON-FINAL ACTION WRITTEN
Sep 6, 2024 CNRT
ASSIGNED TO EXAMINER
Sep 6, 2024 DOCK
TEAS VOLUNTARY AMENDMENT RECEIVED
Aug 12, 2024 PARI
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jun 15, 2024 NWOS
NEW APPLICATION ENTERED
Feb 13, 2024 NWAP